TY - JOUR
T1 - Prognostic radiomic signature for head and neck cancer
T2 - Development and validation on a multi-centric MRI dataset
AU - Bologna, Marco
AU - Corino, Valentina
AU - Cavalieri, Stefano
AU - Calareso, Giuseppina
AU - Gazzani, Silvia Eleonora
AU - Poli, Tito
AU - Ravanelli, Marco
AU - Mattavelli, Davide
AU - de Graaf, Pim
AU - Nauta, Irene
AU - Scheckenbach, Kathrin
AU - Licitra, Lisa
AU - Mainardi, Luca
N1 - Copyright © 2023 Elsevier B.V. All rights reserved.
Funding Information:
Prof. Licitra reports grants and personal fees from ASTRAZENECA, personal fees from BAYER, grants and personal fees from BMS, grants and personal fees from BOEHRINGER INGELHEIM, grants and personal fees from Debiopharm International SA, grants and personal fees from EISAI, grants and personal fees from MERCK-SERONO, grants and personal fees from MSD, grants and personal fees from NOVARTIS, grants and personal fees from ROCHE, personal fees from SOBI, personal fees from IPSEN, personal fees from GSK, personal fees from Doxa Pharma srl, personal fees from Incyte Biosciences Italy srl, personal fees from Amgen, personal fees from Nanobiotics Sa, grants from Celgene International, grants from Exelixis inc, grants from Hoffmann-La Roche ltd, grants from IRX Therapeutics inc, grants from Medpace inc, grants from Pfizer, outside the submitted work. For the remaining authors none were declared.
Publisher Copyright:
© 2023 Elsevier B.V.
PY - 2023/3/31
Y1 - 2023/3/31
N2 - BACKGROUND AND PURPOSE: Prognosis in locally advanced head and neck cancer (HNC) is currently based on TNM staging system and tumor subsite. However, quantitative imaging features (i.e., radiomic features) from magnetic resonance imaging (MRI) may provide additional prognostic info. The aim of this work is to develop and validate an MRI-based prognostic radiomic signature for locally advanced HNC.MATERIALS AND METHODS: Radiomic features were extracted from T1- and T2-weighted MRI (T1w and T2w) using the segmentation of the primary tumor as mask. In total 1072 features (536 per image type) were extracted for each tumor. A retrospective multi-centric dataset (n = 285) was used for features selection and model training. The selected features were used to fit a Cox proportional hazard regression model for overall survival (OS) that outputs the radiomic signature. The signature was then validated on a prospective multi-centric dataset (n = 234). Prognostic performance for OS and disease-free survival (DFS) was evaluated using C-index. Additional prognostic value of the radiomic signature was explored.RESULTS: The radiomic signature had C-index = 0.64 for OS and C-index = 0.60 for DFS in the validation set. The addition of the radiomic signature to other clinical features (TNM staging and tumor subsite) increased prognostic ability for both OS (HPV- C-index 0.63 to 0.65; HPV+ C-index 0.75 to 0.80) and DFS (HPV- C-index 0.58 to 0.61; HPV+ C-index 0.64 to 0.65).CONCLUSION: An MRI-based prognostic radiomic signature was developed and prospectively validated. Such signature can successfully integrate clinical factors in both HPV+ and HPV- tumors.
AB - BACKGROUND AND PURPOSE: Prognosis in locally advanced head and neck cancer (HNC) is currently based on TNM staging system and tumor subsite. However, quantitative imaging features (i.e., radiomic features) from magnetic resonance imaging (MRI) may provide additional prognostic info. The aim of this work is to develop and validate an MRI-based prognostic radiomic signature for locally advanced HNC.MATERIALS AND METHODS: Radiomic features were extracted from T1- and T2-weighted MRI (T1w and T2w) using the segmentation of the primary tumor as mask. In total 1072 features (536 per image type) were extracted for each tumor. A retrospective multi-centric dataset (n = 285) was used for features selection and model training. The selected features were used to fit a Cox proportional hazard regression model for overall survival (OS) that outputs the radiomic signature. The signature was then validated on a prospective multi-centric dataset (n = 234). Prognostic performance for OS and disease-free survival (DFS) was evaluated using C-index. Additional prognostic value of the radiomic signature was explored.RESULTS: The radiomic signature had C-index = 0.64 for OS and C-index = 0.60 for DFS in the validation set. The addition of the radiomic signature to other clinical features (TNM staging and tumor subsite) increased prognostic ability for both OS (HPV- C-index 0.63 to 0.65; HPV+ C-index 0.75 to 0.80) and DFS (HPV- C-index 0.58 to 0.61; HPV+ C-index 0.64 to 0.65).CONCLUSION: An MRI-based prognostic radiomic signature was developed and prospectively validated. Such signature can successfully integrate clinical factors in both HPV+ and HPV- tumors.
KW - Head and neck cancer
KW - Machine learning
KW - MRI
KW - Radiomics
KW - Survival analysis
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85151721456&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/37004837
U2 - 10.1016/j.radonc.2023.109638
DO - 10.1016/j.radonc.2023.109638
M3 - Article
C2 - 37004837
SN - 0167-8140
VL - 183
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
M1 - 109638
ER -